Comparing 18F-AV-1451 with CSF T-tau and P-tau for diagnosis of Alzheimer’s disease. Mattsson N, Smith R, Strandberg O, Palmqvist S, Schöll M, Insel P, Hagerstrom D, Olsson T, Zetterberg H, Blennow K, Jögi J, Hansson O. Neurology (in press).

Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Palmqvist S, Schöll M, Strandberg O, Mattsson N, Stomrud E, Zetterberg H, Blennow K, Landau S, Jagust W, Hansson O. Nature communications (in press).

Amyloid network topology characterizes the progression of Alzheimer’s disease during the pre-dementia stages. Pereira JB, Strandberg TO, Palmqvist S, Volpe G, Westen Dv, Westman E, Hansson O, for the Alzheimer’s Disease Neuroimaging Initiative. Cerebral Cortex (in press).

Performance of Different Amyloid Immunoassays in Predicting Outcome of Visual Assessment of Amyloid PET Imaging. Janelidze S, Pannee J, Mikulskis A, Chiao P, Zetterberg H, Blennow K, Hansson O.  JAMA Neurology (in press).

Atrophy of the posterior subiculum is associated with memory impairment, tau- and Aβ pathology in non-demented individuals. Lindberg O, Mårtensson G, Stomrud E, Palmqvist S, Wahlund L-O, Westman E, Hansson O. Frontiers in Aging Neuroscience. 2017 Sep 20;9:306.

Cerebral hypoperfusion is not associated with an increase in amyloid β pathology in middle-aged or elderly people. Hansson O, Palmqvist S, Ljung H, Cronberg T, van Westen D, Smith R. Alzheimers Dement. 2017 Jul 15. [Epub ahead of print]

In vivo retention of (18)F-AV-1451 in corticobasal syndrome. Smith R, Schöll M, Widner H, van Westen D, Svenningsson P, Hägerström D, Ohlsson T, Jögi J, Nilsson C, Hansson O. Neurology. 2017 Jul 28. [Epub ahead of print]

Distinct 18F-AV- 1451 tau PET retention patterns in early- and late-onset Alzheimer’s disease. Schöll M, Ossenkoppele R, Strandberg O, Palmqvist S, Ohlsson T, Jögi J, Smith R, Hansson O. Brain [Epub online].

18F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer’s disease. Mattsson N, Schöll M, Strandberg O, Smith R, Palmqvist S, Insel PS, Hägerström D, Ohlsson T, Zetterberg H, Jögi J, Blennow K, Hansson O. EMBO Mol Med. 2017 Jul 25. [Epub ahead of print]

Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40). Vanderstichele H, Demeyer L, Janelidze S, Coart E, Stoops E, Mauroo K, Herbst V, François C, Hansson O. Alzheimers Res Ther. 2017 Jun 6;9(1):40. doi: 10.1186/s13195-017-0265-7.

Psychometric testing of a Swedish version of the Apathy Evaluation Scale. Johansson M, Johansson P, Stomrud E, Hagell P, Hansson O. Nord J Psychiatry. 2017 Jun 20:1-8. doi: 10.1080/08039488.2017.1334820. [Epub ahead of print]

The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Ferreira D, Hansson O, Barroso J, Molina Y, Machado A, Hernández-Cabrera JA, Muehlboeck JS, Stomrud E, Nägga K, Lindberg O, Ames D, Kalpouzos G, Fratiglioni L, Bäckman L, Graff C, Mecocci P, Vellas B, Tsolaki M, Kłoszewska I, Soininen H, Lovestone S, Ahlström H, Lind L, Larsson EM, Wahlund LO, Simmons A, Westman E; and for the AddNeuroMed consortium, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI).; Australian Imaging Biomarkers and Lifestyle Study of Ageing (AIBL) research group. Hippocampus. 2017 Jun;27(6):653-667.

Tau oligomers in cerebrospinal fluid in Alzheimer’s disease. Sengupta U, Portelius E, Hansson O, Farmer K, Castillo-Carranza D, Woltjer R, Zetterberg H, Galasko D, Blennow K, Kayed R. Tau oligomers in cerebrospinal fluid in Alzheimer’s disease. Ann Clin Transl Neurol. 2017 Mar 1;4(4):226-235.

Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.  Hansson O, Janelidze S, Hall S, Magdalinou N, Lees AJ, Andreasson U, Norgren N, Linder J, Forsgren L, Constantinescu R, Zetterberg H, Blennow K; Swedish BioFINDER study.  Neurology. 2017 Mar 7;88(10):930-937

Increased blood-brain barrier permeability is associated with dementia and diabetes but not amyloid pathology or APOE genotype.  Janelidze S, Hertze J, Nägga K, Nilsson K, Nilsson C; Swedish BioFINDER Study Group., Wennström M, van Westen D, Blennow K, Zetterberg H, Hansson O.  Neurobiol Aging. 2017 Mar;51:104-112.

Tau Pathology Distribution in Alzheimer’s disease Corresponds Differentially to Cognition-Relevant Functional Brain Networks. Hansson O, Grothe MJ, Strandberg TO, Ohlsson T, Hägerström D, Jögi J, Smith R, Schöll M. Front Neurosci. 2017 Mar 31;11:167.

Tau neuropathology correlates with FDG-PET, but not AV-1451-PET, in progressive supranuclear palsy. Smith R, Schöll M, Honer M, Nilsson CF, Englund E, Hansson O. Acta Neuropathol. Acta Neuropathol. 2017 Jan;133(1):149-151.

Increased basal ganglia binding of of 18F-AV-1451 in patients with progressive supranuclear palsy. Smith R, Schain M, Nilsson C, Strandberg O, Olsson T, Hägerström D, Jögi J, Borroni E, Schöll M, Honer M, Hansson O. Mov Disord. 2017 Jan;32(1):108-114.

Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease. Habchi J, Chia S, Limbocker R, Mannini B, Ahn M, Perni M, Hansson O, Arosio P, Kumita JR, Challa PK, Cohen SI, Linse S, Dobson CM, Knowles TP, Vendruscolo M. Systematic development of small molecules to inhibit specific microscopic steps of Aβ42 aggregation in Alzheimer’s disease. Proc Natl Acad Sci U S A. 2017 Jan 10;114(2):E200-E208.


Plasma tau in Alzheimer disease   Mattsson N, Zetterberg H, Janelidze S, Insel PS, Andreasson U, Stomrud E, Palmqvist S, Baker D, Tan Hehir CA, Jeromin A, Hanlon D, Song L, Shaw LM, Trojanowski JQ, Weiner MW, Hansson O, Blennow K   Neurology. 2016 Oct 25;87(17):1827-1835.

Modeling strategies for quantification of in vivo 18F-AV1451 binding in patients with tau pathology Hahn A, Schain M, Erlandsson M, Sjölin P, James GM, Strandberg OT, Hägerström D, Lanzenberger R, Jögi J, Olsson TG, Smith R, Hansson O,   J Nucl Med. 2016 Oct 20. pii: jnumed.116.174508. [Epub ahead of print]

18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Smith R, Puschmann A, Schöll M, Ohlsson T, van Swieten J, Honer M, Englund E, Hansson O. Brain. 2016 Sep;139(Pt 9):2372-9.

Reply: Do we still need positron emission tomography for early Alzheimer’s disease diagnosis? Palmqvist S, Mattsson N, Hansson O. Brain. 2016 Jul 6. [Epub ahead of print]

Alterations of Diffusion Kurtosis and Neurite Density Measures in Deep Grey Matter and White Matter in Parkinson’s Disease. Surova Y, Lampinen B, Nilsson M, Lätt J, Hall S, Widner H; Swedish BioFINDER study, van Westen D, Hansson O. PLoS One. 2016 Jun 30;11(6):e0157755.

Brain activity and Alzheimer’s disease: a complex relationship. Hansson O, Gouras G. Brain. 2016 Aug;139(Pt 8):2109-10.

Reference measurement procedure for CSF Aβ1-42 and the CSF Aβ1-42 /Aβ1-40 ratio – a cross-validation study against Amyloid PET. Pannee J, Portelius E, Minthon L, Gobom J, Andreasson U, Zetterberg H, Hansson O, Blennow K. J Neurochem. 2016 Aug 31.

Optimized Standard Operating Procedures for the Analysis of Cerebrospinal Fluid Aβ42 and the Ratios of Aβ Isoforms Using Low Protein Binding Tubes. Vanderstichele HM, Janelidze S, Demeyer L, Coart E, Stoops E, Herbst V, Mauroo K, Brix B, Hansson O. J Alzheimers Dis. 2016 May 31;53(3):1121-32.

A Genetic Variant of the Sortilin 1 Gene is Associated with Reduced Risk of Alzheimer’s Disease. Andersson CH, Hansson O, Minthon L, Andreasen N, Blennow K, Zetterberg H, Skoog I, Wallin A, Nilsson S, Kettunen P. J Alzheimers Dis. 2016 Jul 1;53(4):1353-63.

Plasma β-amyloid in Alzheimer’s disease and vascular diseaseJanelidze S,  Stomrud E,  Palmqvist S,   Zetterberg H,  van Westen D,  Jeromin A,  Song L,  Hanlon D,  Tan Hehir C,  Baker D,  Blennow K,  Hansson O. Scientific Report. 2016 May 31;6:26801.

Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer’s disease.
Mattsson N, Insel PS, Palmqvist S, Portelius E, Zetterberg H, Weiner M, Blennow K, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. EMBO Mol Med. 2016 Aug 17.

Cerebral white matter lesions – associations with Aβ isoforms and amyloid PETvan Westen D, Lindqvist D, Blennow K, Minthon L, Nägga K, Stomrud E, Zetterberg H, Hansson O. Scientific Reports. 2016 Feb 9;6:20709.

Posterior Accumulation of Tau and Concordant Hypometabolism in an Early-Onset Alzheimer’s Disease Patient with Presenilin-1 Mutation. Smith R, Wibom M, Olsson T, Hägerström D, Jögi J, Rabinovici GD, Hansson O. J Alzheimers Dis. 2016 Jan 21;51(2):339-43.

Cerebrospinal fluid analysis detects cerebral amyloid-β accumulation earlier than positron emission tomography. Palmqvist S, Mattsson N, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2016 Apr;139(Pt 4):1226-36.

Longitudinal Measurements of Cerebrospinal Fluid Biomarkers in Parkinson’s Disease. Hall S, Surova Y, Öhrfelt A; Swedish BioFINDER Study, Blennow K, Zetterberg H, Hansson O. Movement Disorders. 2016 Feb 16.

Increased amyloidogenic APP processing in APOE ɛ4-negative individuals with cerebral β-amyloidosis. Mattsson N, Insel P, Palmqvist S, Stomrud E, van Westen D, Minthon L, Zetterberg H, Blennow K, Hansson O. Nature Communications. 2016 Mar 7;7:10918.

Early myo-inositol changes may precede Aβ pathology and relate to APOE genotype in Alzheimer disease. O Voevodskaya1, PC Sundgren, O Strandberg, H Zetterberg, L Minthon MD, K Blennow, L-O Wahlund, for the Swedish BioFINDER study group, E Westman and O Hansson. Neurology. 2016 May 10;86(19):1754-61.

CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios improve the diagnostic accuracy for Alzheimer’s diseaseS Janelidze, H Zetterberg, N Mattsson, S Palmqvist, H Vanderstichele, the Swedish BioFINDER study, O Lindberg, D van Westen, E Stomrud, L Minthon, K Blennow, O Hansson. Ann Clin Transl Neurol. 2016 Jan 1;3(3):154-65.



Comparison of Amyloid PET and CSF Biomarkers for Identifying Early Alzheimer’s Disease.
Palmqvist S, Zetterberg H, Mattsson N, Johansson P, for the Alzheimer’s Disease Neuroimaging Initiative, Minthon M, Blennow K, Olsson M, for the Swedish BioFINDER study group, Hansson O. Neurology. 2015 Oct 6;85(14):1240-9.

Increased cerebrospinal fluid biomarkers of angiogenesis in Parkinson’s disease. Janelidze S, Lindqvist D, Francardo V, Hall S,Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, the Swedish BioFINDER study, Cenci A, Hansson O. Neurology, 2015 Nov 24;85(21):1834-42.

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer’s disease: A prospective 9-year study. Stomrud E, Minthon L, Zetterberg H, Blennow K, Hansson O. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring. 2015 1: 4, 403–411.

Cerebrospinal fluid levels of IL-6 are decreased and correlate with cognitive status in DLB patientsWennström M, Hall S, Nägga K, Londos E, Minthon L, Hansson O. Alzheimer’s Research & Therapy. 2015 Oct 5;7(1):63.

Extrapolation-Based References Improve Motion and Eddy-Current Correction of High B-Value DWI Data: Application in Parkinson’s Disease Dementia. Nilsson M, Szczepankiewicz F, van Westen D, Hansson O. PLoS One. 2015 Nov 3;10(11):e0141825

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease. Silajdzic E, Bjorkqvist M, & Hansson O. BMC Neurol 2015, 15:8.

Alzheimer’s disease cerebrospinal fluid biomarker in cognitively normal subjects.
Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P, Blennow K, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative. Brain. 2015 Sep;138(Pt 9):2701-15.

Disease-specific structural changes in thalamus and dentatorubrothalamic tract in progressive supranuclear palsy. Surova Y, Nilsson M, Lätt J, Lampinen B, Lindberg O, Hall S, Widner H, Nilsson C, van Westen D, Hansson O. Neuroradiology. 2015 Nov;57(11):1079-91.

Parkinson’s Disease Case Ascertainment in the EPIC Cohort: The NeuroEPIC4PD Study. Gallo V, Brayne C, Forsgren L, Barker RA, Petersson J, Hansson O, Lindqvist D, Ruffmann C, Ishihara L, Luben R, Arriola L, Bergareche A, Gavrila D, Erro ME, Vanacore N, Sacerdote C, Bueno-de-Mesquita B, Vermeulen R, Seelen M, Sieri S, Masala G, Ramat S, Kyrozis A, Thricopolou A, Panico S, Mattiello A, Kaaks R, Teucher B, Katzke V, Kloss M, Curry L, Calboli F, Riboli E, Vineis P, Middleton L. Neurodegener Dis. 2015;15(6):331-8.

Associations between TOMM40 Poly-T Repeat Variants and Dementia in Cases with Parkinsonism. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O. Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20.

Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer’s disease. Janelidze S, Hertze J, Zetterberg H, Landqvist Waldö M, Santillo A, Blennow K, Hansson O. Ann Clin Transl Neurol. 2015 Nov 20;3(1):12-20.

Cerebral Microbleeds and White Matter Hyperintensities in Cognitively Healthy Elderly: A Cross-sectional Cohort Study Evaluating the Effect of Arterial StiffnessAnna-Märta Gustavsson, Erik Stomrud, Kasim Abul-Kasim, Lennart Minthon, Peter M. Nilsson, Oskar Hansson, Katarina Nägga. Cerebrovascular Diseases EXTRA, 2015;5:41–51.

CSF biomarkers and clinical progression of Parkinson disease. Hall S, Surova Y, Öhrfelt A, Zetterberg H, Lindqvist D, and Hansson O. Neurology, 2015 Jan 6;84(1):57-63.



Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid beta-Amyloid 42Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O. JAMA Neurol. 2014 Oct;71(10):1282-9.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease. Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative. JAMA Psychiatry. 2014;71(10):1183-91.

Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer’s disease patients and controls. Martínez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP, & Nielsen HM. Acta Neuropathologica 2014, 127(5):633-643.

Flt3 ligand does not differentiate between Parkinsonian disorders. Silajdžić E, Constantinescu R, Holmberg B, Björkqvist M, & Hansson O. Movement Disorders 2014, 29(10):1319-1322.

Levels of cerebrospinal fluid alpha-synuclein oligomers are increased in Parkinson’s disease with dementia and dementia with Lewy bodies compared to Alzheimer’s diseaseHansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM. Alzheimer’s Research & Therapy. 2014;6(3):25.

Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. Nielsen HM, Hall S, Surova Y, Nägga K, Nilsson C, Londos E, Minthon L, Hansson O, Wennström MNielsen HM et al. Journal of Alzheimer’s Disease. 2014;40(2):343-50.



Cerebrospinal fluid inflammatory markers in Parkinson’s disease–associations with depression, fatigue, and cognitive impairment. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O. Brain, Behavior, and Immunity. 2013;33:183-9.

Assessment of global and regional diffusion changes along white matter tracts in parkinsonian disorders by MR tractography. Surova Y, Szczepankiewicz F, Lätt J, Nilsson M, Eriksson B, Leemans A, Hansson O, van Westen D, Nilsson C. PloS One. 2013;8(6):e66022.

Low CSF levels of both alpha-synuclein and the alpha-synuclein cleaving enzyme neurosin in patients with synucleinopathy. Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Boström F, Hansson O, Nielsen HM. PloS one. 2013;8(1):e53250.

Abeta1-15/16 as a potential diagnostic marker in neurodegenerative diseasesNutu M, Bourgeois P, Zetterberg H, Portelius E, Andreasson U, Parent S, Lipari F, Hall S, Constantinescu R, Hansson O, Blennow K. et al. Neuromolecular Medicine. 2013;15(1):169-79.